Holen Sie sich die Stockscreener-App
9.80
5.68%
-0.59
Handel nachbörslich:
9.80
Schlusskurs vom Vortag:
$10.39
Offen:
$10.32
24-Stunden-Volumen:
241.55K
Relative Volume:
1.49
Marktkapitalisierung:
$212.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-18.33%
1M Leistung:
-39.05%
6M Leistung:
-23.79%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.7001
$10.38
1-Wochen-Bereich:
$9.7001
$12.05
52-Wochen-Spanne:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Firmenname
Aardvark Therapeutics Inc
Sektor
Branche
Telefon
(858) 225-7696
Adresse
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Vergleichen Sie AARD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
9.80 | 225.39M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-29 | Eingeleitet | Stifel | Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Eingeleitet | BofA Securities | Buy |
| 2025-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-03-10 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
Aardvark Therapeutics Showcases Obesity Research at ObesityWeek - TipRanks
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 - The Manila Times
Aardvark (NASDAQ: AARD) to Start Phase 2 POWER Trial in 2025 for ARD-201 in obesity - Stock Titan
Real time social sentiment graph for Aardvark Therapeutics Inc.July 2025 Pullbacks & Low Risk High Reward Ideas - newser.com
Why Aardvark Therapeutics Inc. stock is seen as undervaluedMarket Activity Summary & Free Daily Entry Point Trade Alerts - newser.com
Will Aardvark Therapeutics Inc. stock attract ESG investorsWeekly Stock Analysis & Free Fast Gain Swing Trade Alerts - newser.com
Is Aardvark Therapeutics Inc. forming a reversal patternJuly 2025 EndofMonth & Reliable Trade Execution Plans - newser.com
Will Aardvark Therapeutics Inc. stock reach Wall Street targetsStock Surge & Momentum Based Trading Signals - newser.com
Using AI based signals to follow Aardvark Therapeutics Inc.July 2025 Price Swings & High Conviction Trade Alerts - newser.com
Analyzing Aardvark Therapeutics Inc. with multi timeframe chartsJuly 2025 Macro Moves & Daily Growth Stock Investment Tips - newser.com
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Aardvark Therapeutics (Nasdaq: AARD) grants inducement options totaling 88,217 shares - Stock Titan
Aardvark Therapeutics (NASDAQ: AARD) sets Nov 11 & Nov 24 investor talks; live webcasts - Stock Titan
Is Aardvark Therapeutics Inc. stock undervalued vs historical averagesTrade Volume Report & Risk Controlled Daily Trade Plans - newser.com
Is Aardvark Therapeutics Inc. stock attractive for income investorsJobs Report & Verified Momentum Stock Ideas - newser.com
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Aardvark Therapeutics Inc. stock beat EPS estimates2025 Sector Review & Real-Time Buy Signal Notifications - newser.com
Is Aardvark Therapeutics Inc. forming a bottoming baseVolume Spike & Weekly Breakout Watchlists - newser.com
Is Aardvark Therapeutics Inc. building a consolidation baseGap Down & Free Long-Term Investment Growth Plans - newser.com
Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study - TipRanks
Finanzdaten der Aardvark Therapeutics Inc-Aktie (AARD)
Es liegen keine Finanzdaten für Aardvark Therapeutics Inc (AARD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):